HUTCHMED DRC
$ 11.45
1.96%
29 May - close price
- Market Cap 1,955,076,000 USD
- Current Price $ 11.45
- High / Low $ 11.54 / 11.12
- Stock P/E 4.29
- Book Value 7.20
- EPS 2.65
- Next Earning Report 2026-06-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.02 %
- ROE 0.45 %
- 52 Week High 19.50
- 52 Week Low 11.10
About
HUTCHMED (China) Limited discovers, develops and markets targeted immunotherapies and therapies for cancer and immune diseases globally. The company is headquartered in Central, Hong Kong.
Analyst Target Price
$22.85
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-28 | 2025-07-02 | 2025-05-28 | 2025-03-19 | 2024-11-29 | 2024-07-31 | 2024-06-10 | 2024-02-28 | 2023-11-10 | 2023-07-31 | 2023-06-20 | 2023-02-28 |
| Reported EPS | 0 | 0.52 | 0 | 0.01 | 0 | 0 | 0 | -0.7 | 0 | 0.97 | 0 | -1.02 |
| Estimated EPS | 0 | 0 | 0 | 0.04 | 0 | 0 | 0 | -1.08 | 0.04 | -0.055 | -0.05 | -1.02 |
| Surprise | 0 | 0.52 | 0 | -0.03 | 0 | 0 | 0 | 0.38 | -0.04 | 1.025 | 0.05 | 0 |
| Surprise Percentage | None% | None% | None% | -75% | None% | None% | None% | 35.1852% | -100% | 1863.6364% | 100% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-06-04 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HCM
2026-05-29 10:40:25
Morgan Stanley has upgraded Hutchmed (China) (HCM.US) to a "Hold" rating while simultaneously reducing its target price to $13.6. This action suggests a more neutral outlook on the stock despite the upgraded rating, indicating potential concerns that led to the price target reduction.
2026-05-27 01:40:07
Hutchmed stock has fallen to a 52-week low of $11.70, marking a 12.08% decline over the past year. Despite this, InvestingPro analysis indicates the stock is undervalued with a P/E ratio of 4.64 and a fair value of $14.06, and the company holds more cash than debt. This recent stock performance occurs alongside strong 2025 full-year earnings, with a consolidated profit of $457 million largely due to Fruquintinib sales and a significant cash position of $1.4 billion.
2026-05-24 22:39:32
HUTCHMED and Innovent Biologics announced that the China National Medical Products Administration (NMPA) has approved their New Drug Application for the combination therapy of ELUNATE (fruquintinib) and TYVYT (sintilimab injection). This approval is for patients with locally advanced or metastatic renal cell carcinoma who have previously failed VEGFR-TKI therapy and have not received PD-1 or PD-L1 inhibitor therapy in the first-line setting. The decision is based on positive data from the FRUSICA-2 study, which met its primary endpoint of progression-free survival.
2026-05-23 00:09:26
BofA Securities analyst Alec Stranahan has maintained a "Buy" rating for Hutchmed (China) (HCM.US) and kept the target price at $20. According to TipRanks data, Stranahan has a 48.6% success rate and an 8.8% average return over the past year. This article shares the analyst's rating and provides disclaimers regarding the informational nature of the content.
2026-05-22 20:09:26
HUTCHMED (00013.HK) announced that it will present new and updated data from several studies of compounds at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 to June 2, 2026. This includes results from a pivotal Phase II study of savolitinib for gastric cancer, which met its primary endpoint, and further analyses of fruquintinib and surufatinib studies. These presentations will cover a diverse range of potential tumor indications.
2026-05-22 09:39:47
HUTCHMED (Nasdaq: HCM) will present extensive oncology clinical data at the 2026 ASCO Annual Meeting, headlined by positive results from a pivotal Phase II study of savolitinib for MET-amplified gastric cancer in China. This study met its primary endpoint with a 32.3% objective response rate and supported a New Drug Application in China that received priority review. Additionally, HUTCHMED will share further analyses of fruquintinib from multiple studies and surufatinib data from investigator-initiated trials across various tumor types, highlighting the company's broad clinical development pipeline.
